• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research

Stem cell therapy may reduce risk of heart attack and stroke in certain heart failure patients, new study shows
Cell therapy, involving adult stem cells from bone marrow, has been shown to reduce the risk of heart attack and stroke in severe heart failure patients, according to a new study.
Source: CNN.com - Health - February 27, 2023 Category: Consumer Health News Source Type: news

Potential Applications of Remote Limb Ischemic Conditioning for Chronic Cerebral Circulation Insufficiency
Conclusion Due to its long-term and often invisible course, CCCI has received less attention than acute cerebral ischemic stroke. However, without appropriate intervention, CCCI may lead to a variety of adverse events. Because the pathophysiological changes associated with CCCI are complex, pharmacological research in this area has been disappointing. Recent research suggests that RLIC, which is less invasive and more well-tolerated than drug treatment, can activate endogenous protective mechanisms during CCCI. In the present report, we reviewed studies related to CCCI (Table 1), as well as those related to stroke and sta...
Source: Frontiers in Neurology - May 2, 2019 Category: Neurology Source Type: research

Plasma stem cell factor levels are associated with risk of cardiovascular disease and death
ConclusionsThis prospective population‐based study demonstrates that subjects with high levels of SCF have a lower risk of cardiovascular events and death. The findings provide clinical support for a protective role of SCF in maintaining cardiovascular integrity.This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - August 26, 2017 Category: Internal Medicine Authors: Harry Bj örkbacka, Ingrid Yao Mattisson, Maria Wigren, Olle Melander, Gunilla Nordin Fredrikson, Eva Bengtsson, Isabel Gonçalves, Peter Almgren, Jens O. Lagerstedt, Marju Orho‐Melander, Gunnar Engström, Jan Nilsson Tags: Original Source Type: research

A Review of Mathematical Models for Muscular Dystrophy: A Systems Biology Approach
Discussion With new developments in computational power and data availability, a growing amount of research is using a systems biology approach to understand pathogenesis and progression of disease. Effective and integrated in vitro and in silico models could inform biological phenomena, even without the need of a living subject. For instance, over the last few decades, collagen hydrogel with muscle derived cells (CHMDCs) have promised to revolutionize in vitro experiments and tissue engineering. For CHMDCs to reach the envisioned use, verification by use of mathematical simulations are needed. Recently while examining sha...
Source: PLOS Currents Muscular Dystrophy - February 16, 2018 Category: Neurology Authors: Matthew Houston Source Type: research

Long-term results of isolated transmyocardial laser revascularization in combination with the intramyocardial autologous bone marrow stem cells injection
AbstractTo evaluate the long-term results of TMLR using a CO2 laser in combination with intramyocardial injection of ABMSC as an isolated procedure in patients with the end-stage coronary artery disease, the study included 20 patients (90% male), with a mean age of 58.4 ± 8.7 years. To assess the long-term results, patients were examined in a hospital. The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Seattle Angina Questionnaire (SAQ) were used. The evolution of laboratory and instrumental indices, as well as medical therapy, was assessed. The end points of the study were death, acute myocardial infar...
Source: Lasers in Medical Science - December 3, 2019 Category: Laser Surgery Source Type: research

Stem cells: what happened to the radical breakthroughs?
Much was promised in the late 1990s, but the challenge of advances such as growing whole human organs has been difficult to deliverIt's 1998 and science is taking big strides. The first cloned mammal, Dolly the Sheep, has just had her first lamb; the first robotically assisted heart surgery has been completed; Furbys have hit the shelves. In a bold announcement, biomedical engineer Professor Michael Sefton declared that within 10 years, scientists would have grown an entire heart, fit for transplant. "We're shooting big," he said. "Our vision is that we'll be able to pop out a damaged heart and replace it as easily as you ...
Source: Guardian Unlimited Science - August 10, 2013 Category: Science Authors: Simon Roach Tags: Biology Medical research Features Stem cells The Observer Science Source Type: news

Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
CONCLUSIONS: This systematic review and meta-analysis found moderate quality evidence that BMSC treatment improves LVEF. Unlike in trials where BMSC were administered following acute myocardial infarction (AMI), we found some evidence for a potential beneficial clinical effect in terms of mortality and performance status in the long term (after at least one year) in people who suffer from chronic IHD and heart failure, although the quality of evidence was low. PMID: 24777540 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 3, 2014 Category: Journals (General) Authors: Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E Tags: Cochrane Database Syst Rev Source Type: research

Stem Cell Factor Gene Transfer Improves Cardiac Function After Myocardial Infarction in Swine Original Articles
Conclusions— Local overexpression of SCF post-MI induces the recruitment of c-kit+ cells at the infarct border area acutely. In the chronic stages, SCF gene transfer was associated with improved cardiac function in a preclinical model of ischemic cardiomyopathy.
Source: Circulation: Heart Failure - January 20, 2015 Category: Cardiology Authors: Ishikawa, K., Fish, K., Aguero, J., Yaniz-Galende, E., Jeong, D., Kho, C., Tilemann, L., Fish, L., Liang, L., Eltoukhy, A. A., Anderson, D. G., Zsebo, K., Costa, K. D., Hajjar, R. J. Tags: Angiogenesis, Myogenesis, Other Treatment, Acute myocardial infarction Original Articles Source Type: research

Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction Original Articles
Conclusions— Surprisingly, in this rat model of acute myocardial infarction, the dose–response relationship for intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75x106 is necessary for efficacy; above this threshold, a 4-fold increase in cell number does not produce greater improvement in LV function or structure. Further increases in cell dose are harmful.
Source: Circulation: Heart Failure - July 21, 2015 Category: Cardiology Authors: Tang, X.-L., Rokosh, G., Sanganalmath, S. K., Tokita, Y., Keith, M. C. L., Shirk, G., Stowers, H., Hunt, G. N., Wu, W., Dawn, B., Bolli, R. Tags: Animal models of human disease, Other Treatment, Acute myocardial infarction Original Articles Source Type: research

Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research

Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy
BackgroundBoth bone marrow–derived mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) improve left ventricular remodeling in porcine models and clinical trials. Using xenogeneic (human) cells in immunosuppressed animals with acute ischemic heart disease, we previously showed that these 2 cell types act synergistically.ObjectivesTo more accurately model clinical applications for heart failure, this study tested whether the combination of autologous MSCs and CSCs produce greater improvement in cardiac performance than MSCs alone in a nonimmunosuppressed porcine model of chronic ischemic cardiomyopathy.Metho...
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 26, 2015 Category: Radiology Source Type: research

Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial
Background: Packed red blood cell (PRBC) transfusion is required in hematology patients treated with chemotherapy for acute leukemia, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). In certain situations like septic shock, hip surgery, coronary disease or gastrointestinal hemorrhage, a restrictive transfusion strategy is associated with a reduction of infection and death. A transfusion strategy using a single PRBC unit has been retrospectively investigated and showed a safe reduction of PRBC consumption and costs. We therefore designed a study to prospectively demonstrate that the tra...
Source: Trials - November 23, 2015 Category: Journals (General) Authors: Sylvain ChantepieJean-Baptiste MearLydia GuittetBenoît DervauxJean-Pierre MarolleauFabrice JardinJean-Jacques DutheilJean-Jacques ParientiJean-Pierre VilqueOumedaly Reman Source Type: research

Long Distance Running Effects On Your Health
Long distance running is becoming more and more popular. Close to two million people every year drag themselves across the finish lines. And that’s just in half marathon races. Runners in these 13.1 mile events have increased six-fold over the past 25 years.  All these amateur athletes think they’re getting really healthy as they work themselves up to full marathons. But the truth is they are cutting years off their life.  You can see it for yourself if you stand at the finish line of any race. The hardcore runners look terrible. They look gaunt and malnourished. They are hunched over and have a stiff awkwa...
Source: Al Sears, MD Natural Remedies - June 20, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Fitness Source Type: news

Pages: 1  2  3